*  Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma - Tabular View - ClinicalTrials.gov
... inserted into a large vein under the skin of the chest or through a vein in the arm to receive dacarbazine. Dacarbazine will be ... inserted into a large vein under the skin of the chest or through a vein in the arm to receive dacarbazine. Dacarbazine will be ... Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 ... Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma. The safety and scientific validity of ...
  https://clinicaltrials.gov/ct2/show/record/NCT00354523
*  Dacarbazine Side Effects
... dacarbazine may cause nausea, diarrhea, and other side effects. This resource describes other possible reactions and explains ... Dacarbazine Side Effects. Some of the possible side effects of dacarbazine can include loss of appetite, vomiting, and hair ... Serious Dacarbazine Side Effects. Some side effects of dacarbazine are potentially serious and should be reported immediately ... An Introduction to Side Effects of Dacarbazine. As with other chemotherapy medicines, dacarbazine (DTIC-Dome®) can cause side ...
  http://skin.emedtv.com/dacarbazine/dacarbazine-side-effects.html
*  Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma - Tabular View -...
Drug: Arm 3: Dacarbazine Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable ... Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma. The safety and ... Drug: ARM 2: L19IL2 + Dacarbazine RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 ... Tumor expression of ED-B FN and tumor uptake of L19IL2 and of Dacarbazine will be assessed via immunohistochemistry and/or ...
  https://clinicaltrials.gov/ct2/show/record/NCT01055522
*  Plus it
... dacarbazine, cisplatin, vinblastine, interleukin-2, and IFN-α) over chemotherapy (dacarbazine, cisplatin, and vinblastine) ... Although dacarbazine is considered the "standard of care," it has a response rate of only 10% to 15% with a response duration ... It is currently not known if dacarbazine prolongs survival in patients with melanoma. Combination chemotherapy in the form of ... Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin ...
  http://clincancerres.aacrjournals.org/content/11/8/3009
*  Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients...
Placebo in combination with dacarbazine. Drug: Dacarbazine 1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 ... Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a ... To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone ... Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients ...
  https://clinicaltrials.gov/ct2/show/NCT00936221
*  Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients...
Placebo BD + Dacarbazine. Placebo twice daily + Dacarbazine Participant Flow: Overall Study Selumetinib 75mg BD +Dacarbazine ... Selumetinib 75mg BD +Dacarbazine. selumetinib 75mg twice daily + Dacarbazine Placebo BD + Dacarbazine. Placebo twice daily + ... Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a ... Selumetinib 75mg BD +Dacarbazine. selumetinib 75mg twice daily + Dacarbazine ...
  https://clinicaltrials.gov/ct2/show/results/NCT00936221
*  A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of...
Results: The recommended dose of L19-IL2 in combination with dacarbazine was defined as 22.5 Mio IU. Toxicity was manageable ... A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of ... A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of ... A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of ...
  http://clincancerres.aacrjournals.org/content/early/2011/12/08/1078-0432.CCR-11-1203
*  Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma ...
Dacarbazine. Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of Drugs. Growth ...
  https://clinicaltrials.gov/ct2/show/NCT00597402
*  Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. - The Christie...
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase ... Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.. Authors:. Lee, Siow ... Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral ... Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine-- ...
  http://christie.openrepository.com/christie/handle/10541/99942
*  Dacarbazine - Wikipedia
"Dacarbazine". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ British national formulary : BNF 69 (69 ... Dacarbazine (DTIC), also known as imidazole carboxamide, is a chemotherapy medication used in the treatment of melanoma and ... As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma,[5][6] and as part of ... Dacarbazine works by methylating guanine at the O-6 and N-7 positions.[14] Guanine is one of the four nucleotides that makes up ...
  https://en.wikipedia.org/wiki/Dacarbazine
*  DBL Dacarbazine for Injection (Powder for injection)
... is a brand of medicine containing the active ingredient Dacarbazine. Find out about side effects, who ca... ... How DBL™ Dacarbazine for Injection is given. How much is given. Your doctor will decide what dose of dacarbazine you will ... DBL™ Dacarbazine for Injection is available only with a doctor's prescription.. Before you are given DBL™ Dacarbazine for ... What DBL™ Dacarbazine for Injection is used for. Dacarbazine belongs to a group of medicines known as antineoplastic or ...
  https://www.nps.org.au/medical-info/medicine-finder/dbl-dacarbazine-for-injection-powder-for-injection
*  Dacarbazine Lyophilisate For Solution For Injection 100Mg Drug Medication Dosage Information
... Learn about reported side effects ... Reported Side Effects for Dacarbazine 100mg Powder for Injection. Close Blood Clot Incidence: ,1.0%* Severity: SEVERE Onset: ... DACARBAZINE (da KAR ba zeen) is a chemotherapy drug. This medicine is used to treat skin cancer. It is also used with other ...
  https://www.cvs.com/drug/dacarbazine/lyophilisate-for-solution-for-injection/100mg
*  Bevacizumab vs Dacarbazine in Metastatic Melanoma - Full Text View - ClinicalTrials.gov
Bevacizumab vs Dacarbazine in Metastatic Melanoma. This study has been terminated. (Lack of financing of the study drug. Not ... Drug Information available for: Propranolol Dacarbazine Enalapril Enalapril maleate Enalaprilat Bevacizumab Genetic and Rare ... A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, ... Active Comparator: Dacarbazine Dacarbazine 1000mg/m2 q3w. Drug: Dacarbazine dacarbazine 1000 mg/m2 q3w ...
  https://clinicaltrials.gov/ct2/show/NCT01705392?term=%22High+Blood+Pressure%22&lup_s=03%2F08%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  Dacarbazine (CAS 4342-03-4) Market Research Report 2018
Market Research Report 2018 aims at providing comprehensive data on dacarbazine market globally and regionally (Europe, ... Dacarbazine prices in North America. 6.4. Dacarbazine prices in other regions. 7. DACARBAZINE END-USE SECTOR 7.1. Dacarbazine ... Dacarbazine market forecast. 6. DACARBAZINE MARKET PRICES. 6.1. Dacarbazine prices in Europe. 6.2. Dacarbazine prices in Asia ... Dacarbazine application spheres, downstream products. 3. DACARBAZINE MANUFACTURING METHODS. 4. DACARBAZINE PATENTS. Abstract. ...
  https://marketpublishers.com/report/industry/chemicals_petrochemicals/dacarbazine_4342-03-4_market_research_report.html
*  Dr. George Demetri on the Mutagenic Properties and Future Potentials of Dacarbazine
... on the mutagenic properties of dacarbazine. Demetri says recent studies have revealed that dacarbazine is much more useful in ... Demetri believes that dacarbazine's unique properties may play an additional role in finding ways to utilize chemotherapy as a ... Demetri adds that the mutagenic properties of dacarbazine are so prevalent that he hopes future studies might be able to take ...
  http://www.targetedonc.com/videos/dr-george-demetri-mutagenic-properties-dacarbazine
*  Dacarbazine / dacarbazine NDA 075940 global drug patent coverage, generic alternatives and suppliers
Additional details are available on the DACARBAZINE profile page. The generic ingredient in DACARBAZINE is dacarbazine. There ... DACARBAZINE. dacarbazine. INJECTABLE;INJECTION. 075940. ANDA. Hospira Worldwide, Inc.. 61703-327. N. 61703-327-22. ... NDA 075940 describes DACARBAZINE, which is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hospira, Teva Pharms Usa, and ...
  https://www.drugpatentwatch.com/p/NDA/075940
*  Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma - Study Results -...
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma. The safety and ... Dacarbazine was given up to Week 22 and was not given in the Maintenance Phase. Participants who experienced PD or who did not ... Placebo and Dacarbazine. Placebo: Intravenous solution; intravenous; 0 mg; 1 dose every 3 weeks for 10 weeks, then 1 dose every ... Placebo and Dacarbazine. Placebo: Intravenous solution; intravenous; 0 mg; 1 dose every 3 weeks for 10 weeks, then 1 dose every ...
  https://clinicaltrials.gov/ct2/show/results/NCT00324155?sect=Xd0156&view=results
*  Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma - Full Text View -...
Active Comparator: Dacarbazine, 1000 mg/m^2 Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 ... dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma. Condition or disease Intervention/ ... Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066). ... Drug Information available for: Dacarbazine Nivolumab Genetic and Rare Diseases Information Center resources: Carcinoid Tumor ...
  https://clinicaltrials.gov/show/NCT01721772
*  Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That...
Drug: Cabozantinib S-malate Drug: Dacarbazine Other: Laboratory Biomarker Analysis Drug: Temozolomide Phase 2 ... Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, ... If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in ... Dacarbazine. Imidazole. Antineoplastic Agents, Alkylating. Alkylating Agents. Molecular Mechanisms of Pharmacological Action. ...
  https://clinicaltrials.gov/show/NCT01835145
*  A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma - Full Text...
Active Comparator: Dacarbazine Drug: Dacarbazine Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route= ... A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma. The safety and ... Dacarbazine will be administered at a dose of 1.0 g/m^2 as a 20-120 minute infusion, once every 3 weeks, until disease ... Drug Information available for: Dacarbazine Trabectedin Genetic and Rare Diseases Information Center resources: Soft Tissue ...
  https://clinicaltrials.gov/ct2/show/study/NCT01343277
*  Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma - Full Text View -...
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma. The safety and ... Experimental: Arm A: Ipilimumab and Dacarbazine In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to ... or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo. ... Drug: Dacarbazine Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression ...
  https://clinicaltrials.gov/ct2/show/NCT00324155